I agree definitely - the risk-to-benefit ratio of CHM right now from what we already know and can imply is too favoured towards the benefit side that it's hard not to be excited.
Let's see how we go with Phase 1 and that should be the first significant catalyst for CHM.
Ann: FIRST MILESTONE ON PATH TO CDH17 CAR T CLINICAL TRIAL, page-14
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $9.068M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.5¢ | 0.4¢ | $3.434K | 846.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 4945717 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 18599873 | 22 |
View Market Depth
| Last trade - 12.27pm 26/06/2025 (20 minute delay) ? |
| CHM (ASX) Chart |